Retatrutide's Weight-Loss Curve: When (or Whether) It Plateaus

One of the more striking features of the retatrutide Phase 2 data is that at 48 weeks — the trial's endpoint — the weight loss curve hadn't clearly plateaued at the highest dose. Participants were still losing weight as the trial ended. That's different from what the semaglutide and tirzepatide curves look like at comparable timepoints, and it raises a legitimate question: how much weight loss does retatrutide ultimately produce, and does it ever stop?

The honest answer is that we don't have long enough data to know for certain. But what we do know is interesting, and understanding what the 48-week curve actually shows is important before the extrapolations get too speculative.

What "Plateau" Means in Weight-Loss Trials

In GLP-1 receptor agonist trials, weight loss follows a characteristic pattern:

1. Rapid early loss in the first few months as appetite suppresses, caloric intake drops, and the drug reaches therapeutic concentration
2. Continued but slowing loss through months 4–9 as the body begins to defend its lower weight setpoint through metabolic adaptation
3. Plateau where weight loss slows to near-zero — the body's reduced energy expenditure at lower weight eventually matches the reduced caloric intake driven by the drug

The plateau isn't a failure — it's a biological equilibrium. At plateau, the body is maintaining the lower weight, which is the goal. But understanding when and where the plateau occurs tells you the drug's ceiling and how long you'll continue to see meaningful change on the scale.

For semaglutide (STEP-1): Mean weight loss at the 2.4 mg dose appeared to plateau by approximately weeks 52–60, with most of the loss achieved by week 48. The 68-week endpoint captured a curve that had largely flattened.

For tirzepatide (SURMOUNT-1): The 15 mg dose continued losing through approximately week 52–60, with the curve flattening somewhat by 72 weeks. The higher efficacy is partly because the plateau was reached at a lower body weight (larger total loss) and partly because the curve stayed in the steeper portion longer.

The Retatrutide 48-Week Picture

The Phase 2 trial published by Jastreboff et al. in NEJM (2023) enrolled 338 adults across five dose arms — 1 mg, 3 mg, 4 mg, 8 mg, and 12 mg weekly — with a 48-week duration. The headline from the trial was the ~24.2% mean weight loss at 48 weeks in the 12 mg arm.

The slope of the curve at 48 weeks:

• At the 12 mg dose, the curve at 48 weeks was still descending — not horizontal. Participants had not reached apparent steady-state weight. The rate of loss had slowed from the early months, as expected, but had not plateaued.
• At lower doses (4 mg and 8 mg), the curves appeared closer to plateau at 48 weeks — consistent with a dose-response relationship where the lower doses exhaust their effect sooner.

This is what sets retatrutide apart from semaglutide and somewhat from tirzepatide: at the highest dose, the trial ended before the weight loss curve had clearly flattened. That raises the question of what the eventual plateau weight would be with longer treatment.

What the TRIUMPH-1 Phase 3 Data Adds

The Phase 3 TRIUMPH-1 trial ran at 48 weeks, consistent with the Phase 2 duration. Topline results confirmed approximately 24% mean weight loss at the highest dose, in line with Phase 2, but in a substantially larger and more diverse population.

Critically, the Phase 3 data at 48 weeks showed a similar pattern: continued weight loss trajectory without a clearly established plateau at the highest dose.

The implication is that:

• The ~24% figure at 48 weeks is probably not the final number for retatrutide at 12 mg
• Longer-duration trials (72–100 weeks) at this dose would likely show continued loss
• The eventual plateau is unknown based on current data

This is not a claim that retatrutide produces unlimited weight loss — biology doesn't work that way. It's a claim that the 48-week number is likely a point on the curve, not the floor.

How This Compares to STEP and SURMOUNT

The comparison table that matters for this question:

The cross-trial comparison has the usual caveats — population, era, geographic distribution, and trial design differ across these studies, so the numbers aren't directly head-to-head. But the observation about the curve status at the trial endpoint is a property of the data, not an artifact of trial design: STEP-1 captured a plateau, SURMOUNT-1 captured a flattening, and the retatrutide Phase 2 captured a still-active decline.

If extrapolated — carefully — this suggests that retatrutide's weight-loss ceiling, when reached, could be above tirzepatide's. The Phase 2 author commentary in NEJM suggested that based on the curve trajectory, the 12 mg dose might approach 25–30% or higher with sufficient duration. That's speculative, but the trajectory supports it.

The Extrapolation Caveats

Before taking any extrapolation too literally, several constraints apply:

Metabolic adaptation becomes more powerful at greater degrees of weight loss. The body doesn't yield each successive 5% loss as easily as the first 5%. At some point below 24%, the energy deficit imposed by retatrutide's appetite suppression will be matched by reduced energy expenditure, and weight loss will stop regardless of drug dose. The Phase 2 data doesn't show where this happens — but it will happen.

The Phase 2 population was 338 people. Mean values in small samples can be misleading about population-level outcomes. The Phase 3 TRIUMPH-1 is larger and confirmed the ~24% figure, but longer-duration Phase 3 data is still pending.

Individual variation is substantial. The mean curve is a useful summary, but the distribution around it is wide. Some participants at 12 mg were at the plateau early; others were still losing at 48 weeks. Predicting where any individual ends up requires data that isn't available from the current trial design.

Tolerability at the highest dose may limit real-world outcomes. Phase 2 dropout rates at 12 mg were higher than at lower doses, largely due to GI side effects. The population that remained on 12 mg through 48 weeks may not represent the full enrolled population, and real-world patients may not tolerate the highest dose as well as trial participants with close monitoring.

Why an Unflattened Curve at 48 Weeks Matters Clinically

The practical significance of this observation depends on what you're using retatrutide for:

For patients who've plateaued on semaglutide or tirzepatide: The unflattened curve at 48 weeks suggests that patients who've stopped losing weight on lower-efficacy drugs might continue losing on retatrutide for longer — and might ultimately reach a lower set-point weight. This is one of the most clinically relevant arguments for retatrutide's eventual position in the treatment sequence.

For patients with very high baseline BMI: People with BMI > 45 may need very large absolute weight losses to reduce comorbidity risk meaningfully. A drug that continues losing beyond the 20% mark is relevant for this population in a way that semaglutide's 15% ceiling isn't.

For understanding treatment duration: If the curve is still active at 48 weeks, stopping treatment at that point means stopping before the plateau is reached. The weight regain after stopping data for GLP-1 agonists suggests regain happens quickly when the drug is stopped — stopping a drug before the plateau may mean stopping before you've captured the full benefit. Whether that matters for long-term outcomes is an open question.

What We'll Know From Future TRIUMPH Data

The ongoing TRIUMPH program includes extensions and subsequent trial arms that will provide longer-duration data at the Phase 3 dose range. Specifically:

• Extension cohorts that continue treatment beyond 48 weeks will establish where the plateau actually occurs
• Maintenance cohorts will test whether weight is maintained long-term at plateau and what happens to the curve if the dose is reduced

Until that data is available, the 48-week curve is the data we have — and it's meaningful precisely because it's incomplete. The curve being unflattened at 48 weeks is informative about the drug's potential ceiling, even if it doesn't establish it.

For the context on what the 24% figure comes from and how TRIUMPH-1 is structured, see TRIUMPH-1 decoded. For how retatrutide's weight-loss profile compares directly to tirzepatide's, retatrutide vs tirzepatide covers the cross-trial comparison in detail.

Related reading

• Retatrutide vs tirzepatide efficacy
• Weight-loss plateau troubleshooting
• Weight regain after stopping GLP-1s